Catumaxomab, a monoclonal bispecific trifunctional antibody, was approved in the European Union in April 2009 for the intraperitoneal treatment of patients with malignant ascites. The marketing authorization holder Fresenius Biotech GmbH developed catumaxomab (Removab(®)) together with its partner TRION Pharma GmbH, Germany. It is the first substance worldwide with a regulatory label for the treatment of malignant ascites due to epithelial carcinomas. Since the peritoneum is of mesothelial origin and therefore lacks EpCAM expression, the intraperitoneal administration of catumaxomab is an attractive targeted immunotherapeutic approach. Catumaxomab is able to destroy EpCAM positive tumor cells in the peritoneal cavity known as the main cause of malignant ascites. In addition, catumaxomab is a potential therapeutic option for several primary tumors since the EpCAM molecule is expressed on the majority of epithelial carcinomas. This review focuses on the clinical development of catumaxomab and indicates future directions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2840231 | PMC |
| http://dx.doi.org/10.4161/mabs.2.2.11221 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An Unusual Case of Chylous Ascites.
Cureus
December 2024
Hepatology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, USA.
Chylous ascites occur when the lymphatic flow is blocked or disrupted, causing a leakage of fluid into the peritoneal space. It can be caused by a number of etiologies and identifying the exact cause can be challenging. We present the case of a 77-year-old man who presented with chylous ascites.
View Article and Find Full Text PDFUnusual recurrence in advanced ovarian cancer after interval cytoreductive surgery and HIPEC.
BMJ Case Rep
January 2025
Surgical Oncology, Aster Hospitals Inc, Bangalore, Karnataka, India.
Ovarian cancer is the second most fatal gynaecological malignancy. The relapses after treatment of ovarian cancer usually occur within 2 years after completion of the first-line therapy. Recurrent ovarian cancer commonly presents as peritoneal surface deposits in the abdomen with or without ascites.
View Article and Find Full Text PDFConservative management of large-volume chylous ascites following a robotic-assisted left radical nephrectomy.
BMJ Case Rep
January 2025
Urology, East Sussex Healthcare NHS Trust, Eastbourne, UK.
Chyle leak is a rare complication following nephrectomy and may result in chylous ascites. A patient in her 70s was diagnosed with a left renal tumour and underwent a robotic-assisted radical nephrectomy. She presented 9 days post discharge with chyle leaking from the left port site wound, which settled after 2 days of inpatient monitoring.
View Article and Find Full Text PDFDeciphering neutrophil heterogeneity in human blood and tumors: Methods for isolating neutrophils and assessing their effect on T-cell proliferation.
Methods Cell Biol
January 2025
de Duve Institute, Université catholique de Louvain, Brussels, Belgium. Electronic address:
Neutrophils were historically considered a homogenous population of cells with functions limited to innate immunity against external threats. However, with the rise of immunotherapy, recent works have shown that neutrophils are also important actors in immuno-oncology. In this context, neutrophils appear as a more heterogenous population of cells.
View Article and Find Full Text PDFPan-TRK positive uterine sarcoma in immunohistochemistry without neurotrophic tyrosine receptor kinase gene fusions: A case report.
World J Clin Cases
January 2025
Department of Obstetrics and Gynecology, Keimyung University School of Medicine, Daegu 42601, South Korea.
Background: The classification of uterine sarcomas is based on distinctive morphological and immunophenotypic characteristics, increasingly supported by molecular genetic diagnostics. Data on neurotrophic tyrosine receptor kinase () gene fusion-positive uterine sarcoma, potentially aggressive and morphologically similar to fibrosarcoma, are limited due to its recent recognition. Pan-TRK immunohistochemistry (IHC) analysis serves as an effective screening tool with high sensitivity and specificity for -fusion malignancies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!